

Sangamo Therapeutics Logo

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

November 5, 2020

BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 5, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:

- **29th Annual Credit Suisse Virtual Healthcare Conference**

Presentation Date: Monday, November 9th at 5 p.m. Eastern Time

- **Barclays Gene Editing & Gene Therapy Summit**

Presentation Date: Monday, November 16th at 10:45 a.m. Eastern Time

Presentations will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under [Events and Presentations](#). The presentation will also be available on the Sangamo website after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, *ex vivo* gene-edited cell therapy, and *in vivo* genome editing and genome regulation. For more information about Sangamo, visit www.sangamo.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201105005222/en/): <https://www.businesswire.com/news/home/20201105005222/en/>

Investor Relations & Media Inquiries

Aron Feingold

628.252.7494

afeingold@sangamo.com

Source: Sangamo Therapeutics, Inc.